SMARCA4 and non-small cell lung carcinoma: Most previous studies in this field have focused on SMARCA4‐deficient thoracic tumors or NSCLC, whereas our study explored the potential value of SMARCA4 as a prognostic marker in LUAD, which has clear innovative and clinical application value.